Mannkind Corp
NASDAQ: MNKD
$7.44
+$0.18 (+2.5%)
Closing Price on November 6, 2024
MNKD Articles
Between the July 15 and July 31 settlement dates, a modest increase in short interest was enough for AMD to rise to the top of the list of the most heavily shorted stocks traded on the Nasdaq.
Published:
MannKind reported a smaller than expected second-quarter net loss before the markets opened on Monday.
Published:
ThinkstockThe short interest data are out for the July 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or break...
Published:
Last Updated:
GallupAll of the top ten most shorted stocks on the NASDAQ had short interests of over 60 million shares, for the period which ended July 15. Not surprisingly, the largest industry represented in...
Published:
24/7 Wall St. has reviewed the short interest in top biotech companies, without focusing on speculative companies.
Published:
Between the June 15 and June 30 settlement dates, the short interest increased in all but one of the six most heavily shorted stocks traded on the Nasdaq.
Published:
The short interest data are out for the June 15 settlement date, and overall, short interest in the selected biotech stocks was mixed.
Published:
Between the May 15 and May 29 settlement dates, Sirius XM was dethroned as the most heavily shorted stock traded on the Nasdaq.
Published:
The markets were in a frenzy Wednesday. However, there were a few companies holding back the rally.
Published:
The May 29 short interest data have been compared with the previous figures, and for most of the selected biotech stocks, short interest has decreased.
Published:
Between the May 15 and May 29 settlement dates, Mannkind continued its climb up the ranks of the most heavily shorted stocks traded on the Nasdaq.
Published:
MannKind remains one of the biggest battleground stocks out there in the realm of biotech and emerging pharmacueticals.
Published:
After finally getting FDA clearance for the inhalable insulin Afrezza, and after a very slow start to the diabetes market, MannKind shares have now nearly doubled from their 52-week low.
Published:
24/7 Wall St. wanted to review some of the most aggressive analyst upgrades and rehashed ratings where analysts were calling for huge upside going into summer.
Published:
The short interest data are out for the May 15 settlement date. Biotech companies are considered a riskier group of stocks.
Published: